Espero Pharmaceuticals Announces Board and Executive Appointments
Wednesday, February 17, 2016
JACKSONVILLE, Fla.--(Business Wire)--Espero Pharmaceuticals, Inc., (http://www.esperopharma.com) a privately held specialty pharmaceutical company, today announced the appointment of industry veteran Wayne Yetter as a member of the board of directors.
Mr. Yetter has more than 30 years of industry experience, with leadership positions at global pharmaceutical companies including President and CEO of Novartis Pharmaceutical Corporation and founding CEO of Astra Merck, now AstraZeneca. He was previously an executive committee member of the Pharmaceutical Research and Manufacturers Association, and held chairman and executive positions at companies that include IMS Health, Odyssey Pharmaceuticals, NuPathe and Noven Pharmaceuticals. Mr. Yetter currently serves as a director of InfuSystem Holdings and Strategic Diagnostics.
“Wayne’s insight and experience will be an invaluable addition to our board and management team as we commercialize our first products,” said Quang Pham, CEO. “His depth of industry knowledge will help advance our business as we bring proven compounds in novel delivery formulations to the U.S. marketplace.”
In addition, Mr. Jeff Cole, Co-Founder of Espero, has been named President and Chief Financial Officer and appointed to the board of directors. He is a senior executive with more than 24 years of experience in finance, business development and commercial operations at companies including Valeant Pharmaceuticals, Solco Healthcare US, and Legacy Pharmaceuticals. His positions at Valeant included CFO North America, and General Manager of the US Specialty Division. As President of Solco Healthcare US, Mr. Cole launched and managed this generic pharmaceutical subsidiary of Legacy Pharmaceuticals.
Mr. Sean Purdy has also been appointed Vice President of Commercial Operations. Mr. Purdy’s 25 years of experience in commercial operations within the pharmaceutical industry includes selling in the cardiovascular, pediatric, and women’s health categories. Prior to joining Espero, he spent six years at Arbor Pharmaceuticals, most recently as the Cardiovascular National Sales Director, leading and helping build a team of approximately 250 sales representatives and managers. In his roles at Arbor and Shionogi, Mr. Purdy managed selling and marketing efforts within the chronic stable angina market, promoting Nitrolingual® Pumpspray, Espero’s first commercially marketed product.
“We are delighted to welcome Sean and add to Jeff’s responsibilities, during this exciting period of growth for the Company,” Mr. Pham said. “Sean will lead our market development initiatives, building on a track record of success with his expertise and broad commercial experience. Jeff’s proven leadership within the industry will enable Espero to realize our goals.”
Espero Pharmaceuticals recently announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for its nitroglycerin sublingual powder for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. The FDA has set an action date of June 10, 2016 to complete its review, as per the Prescription Drug User Fee Act.
Espero Pharmaceuticals, Inc., headquartered in Jacksonville, Florida, is an emerging growth specialty pharmaceutical company engaged in maximizing the commercial value of proven treatments that improve the quality of life for patients. Espero is focused on compounds with proven safety and efficacy administered via novel delivery solutions in the cardiovascular and other specialty therapeutic categories.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160217005305/en/
MBS Value Partners, LLC for Espero Pharmaceuticals, Inc.
Jane Searle, 212-710-9686